VUNO inc, discovered novel artificial intelligence-based electrocardiogram (ECG) analysis software VUNO Med®-DeepECG™.
With the help of deep learning, the software can analyse ECG data to zero in on heart failure, myocardial infarction and arrhythmia.
VUNO Med®-DeepECG™ can even detect a minute difference in ECG data which cannot be possible using visual analysis for patients suffering with heart failure, myocardial infarction and other major heart-related disorders.
VUNO Med®-DeepECG™, applicable in clinical practice helps reduce major mortality rates related to heart diseases and improves the quality life of patients by detecting symptomless patients by making use of ECG testing and timely treatment.
The device can even detect additional information regarding heart failure which cannot be detected through previous ECGs for identifying myocardial infarction even if no major deflections in the ECG wave patterns can be seen.
Korean Ministry of Food and Drug Safety (KFDA) has designated breakthrough device designation for artificial intelligence-based electrocardiogram (ECG) analysis software VUNO Med®-DeepECG™.